Company news

Kalaris Therapeutics, Inc. news in 2025

Kalaris Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

December 17, 2025

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

December 17, 2025

Kalaris to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference

November 24, 2025

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

November 12, 2025

Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer

November 3, 2025

Kalaris to Present at Stifel 2025 Annual Healthcare Conference

October 30, 2025

UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

September 15, 2025

Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

September 15, 2025

Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 13, 2025

Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference

June 2, 2025

Kalaris to Participate at Stifel Ophthalmology Forum

May 23, 2025

Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights

May 14, 2025

Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee

April 4, 2025

Kalaris Announces Closing of Merger with AlloVir

March 18, 2025

Kalaris and AlloVir Announce Stockholder Approval of Merger

March 11, 2025

Decks in 2025